Xencor, Inc. (XNCR) to Release Earnings on Monday

Xencor, Inc. (NASDAQ:XNCR) is set to post its quarterly earnings results after the market closes on Monday, July 31st. Analysts expect Xencor to post earnings of ($0.28) per share for the quarter.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.06. The company had revenue of $4.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a return on equity of 5.98% and a net margin of 18.19%. On average, analysts expect Xencor to post $-1.220 EPS for the current fiscal year and $-1.660 EPS for the next fiscal year.

Xencor, Inc. (NASDAQ XNCR) opened at 23.665 on Friday. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The firm has a market capitalization of $1.11 billion, a PE ratio of 67.040 and a beta of 2.13. The firm’s 50-day moving average is $22.21 and its 200-day moving average is $23.17.

Several equities research analysts have commented on the stock. Wedbush restated an “outperform” rating and set a $29.00 target price on shares of Xencor in a research report on Friday, June 16th. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Xencor presently has a consensus rating of “Buy” and an average price target of $28.67.

In related news, Director Bruce L. A. Carter sold 20,000 shares of the business’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $20.61, for a total value of $412,200.00. Following the sale, the director now directly owns 48,880 shares in the company, valued at approximately $1,007,416.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Edgardo Baracchini, Jr. sold 10,568 shares of the business’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $26.01, for a total transaction of $274,873.68. Following the completion of the sale, the insider now owns 9,818 shares in the company, valued at $255,366.18. The disclosure for this sale can be found here. Insiders sold a total of 45,334 shares of company stock worth $1,014,282 over the last quarter. Insiders own 4.03% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Xencor, Inc. (XNCR) to Release Earnings on Monday” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/07/29/xencor-inc-xncr-to-release-earnings-on-monday.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Earnings History for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply